Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity.
Brian OrrHaider MahdiYusi FangMary StrangeIbrahim UygunMainpal RanaLixin ZhangAdria Suarez MoraAlexandra PusateriEsther ElishaevChaeryon KangGeorge TsengWilliam E GoodingRobert P EdwardsPawel KalinskiAnda M VladPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The chemokine-modulating intraperitoneal-CITC is safe, tolerable, and associated with ISG changes that favor CTL chemoattraction and function. This combination (plus DC vaccine) will be tested in a phase II trial. See related commentary by Aranda et al., p. 1993.